MSB 7.69% $1.19 mesoblast limited

AFR"Long-term backersDespite Mesoblast’s failure to date to get...

  1. 4,445 Posts.
    lightbulb Created with Sketch. 340

    AFR

    "Long-term backers

    Despite Mesoblast’s failure to date to get its drug approved in the US, it has attracted a clutch of long-term backers, including Alex Waislitz’s Thorney Capital (Waislitz shared an apartment in New York years ago with Itescu), M&G Investors, and former Independent Asset Management founder Greg Matthews.

    Its retail supporters had remained optimistic in the lead-up to the FDA decision. Threads on HotCopper, an online stock chat platform, set up this week include “How will you celebrate when the FDA gives the Tick” and “2023: The Final Countdown”.

    By Thursday afternoon, when no FDA update had been provided, the mood was becoming slightly less upbeat. “If the announcement does not have ‘Approved’ in the title, The End,” wrote one poster, though with far fewer comments and views than the others."

    LINK


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.